{"nctId":"NCT00087516","briefTitle":"Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)","startDateStruct":{"date":"2004-06"},"conditions":["Diabetes Mellitus, Type 2"],"count":741,"armGroups":[{"label":"Sitagliptin 100 mg/100 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Sitagliptin (MK0431)","Drug: Metformin - Rescue"]},{"label":"Sitagliptin 200 mg/200 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Sitagliptin","Drug: Metformin - Rescue"]},{"label":"Placebo/Sitagliptin 100 mg","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Metformin - Rescue"]},{"label":"Placebo/Sitagliptin 200 mg","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Metformin - Rescue"]}],"interventions":[{"name":"Sitagliptin (MK0431)","otherNames":["MK0431","Januvia"]},{"name":"Sitagliptin","otherNames":["MK0431","Januvia"]},{"name":"Placebo","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Metformin - Rescue","otherNames":["Metformin","Glucophage","Glucophage XR","Glumetza","Fortamet","Riomet"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with type 2 diabetes mellitus\n* Patient is not pregnant or breastfeeding\n* Male or female patient unlikely to conceive\n* Patient not on an antihyperglycemic drug\n\nExclusion Criteria:\n\n* Patient has history of type 1 diabetes mellitus\n* Patient has history of ketoacidosis\n* Patient requires insulin within 8 weeks prior to start of study\n* Patient on weight loss program and is not in maintenance phase\n* Patient taking weight loss medication within 8 weeks prior to start of study\n* Patient on or likely to require = 14 days or repeated courses of corticosteroids\n* Patient taking immunosuppressive/immunomodulating medication\n* Patient taking digoxin or other cardiac medication\n* Patient has undergone surgical general anesthesia within 30 days prior to start of study\n* Patient taking investigational drug within 8 weeks prior to start of study\n* Patient is diagnosed with liver disease\n* Patient has chronic myopathy, progressive neurological/neuromuscular disorder\n* Patient has with severe cardiac conditions within the last 6 months\n* Patient is Human immunodeficiency virus (HIV) positive\n* Patient has hematological disorder\n* Patient has history of malignancy\n* Patient has history of alcohol or drug abuse within the past 3 years","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in A1C at Week 24","description":"A1C is measured as a percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.61","spread":null},{"groupId":"OG001","value":"-0.76","spread":null},{"groupId":"OG002","value":"0.18","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FPG at Week 24","description":"Change from baseline at Week 24 is defined as Week 24 FPG minus Week 0 FPG.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.4","spread":null},{"groupId":"OG001","value":"-16.6","spread":null},{"groupId":"OG002","value":"4.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 2-hour Post-meal Glucose (2-hr PMG) at Week 24","description":"Change from baseline at Week 24 is defined as Week 24 2-hr PMG minus Week 0 2-hr PMG.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-48.9","spread":null},{"groupId":"OG001","value":"-56.3","spread":null},{"groupId":"OG002","value":"-2.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in A1C at Week 104","description":"A1C is measured as a percent. Thus, this change from baseline reflects the Week 104 A1C percent minus the Week 0 A1C percent.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.27","spread":null},{"groupId":"OG001","value":"-0.40","spread":null},{"groupId":"OG002","value":"-0.32","spread":null},{"groupId":"OG003","value":"-0.34","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FPG at Week 104","description":"Change from baseline at Week 104 is defined as Week 104 FPG minus Week 0 FPG.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":null},{"groupId":"OG001","value":"-5.7","spread":null},{"groupId":"OG002","value":"-4.1","spread":null},{"groupId":"OG003","value":"-4.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 2-hr PMG at Week 104","description":"Change from baseline at Week 104 is defined as Week 104 2-hr PMG minus Week 0 2-hr PMG.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.5","spread":null},{"groupId":"OG001","value":"-41.5","spread":null},{"groupId":"OG002","value":"-38.3","spread":null},{"groupId":"OG003","value":"-35.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":24,"n":238},"commonTop":["Upper Respiratory Tract Infection","Dizziness","Nasopharyngitis","Influenza","Headache"]}}}